Here's why they think that AbbVie (NYSE: ABBV), Exelixis (NASDAQ: EXEL), and Vertex Pharmaceuticals (NASDAQ: VRTX) are stocks to buy hand over fist in December. Prosper Junior Bakiny (AbbVie): The end of the year is always a great time to review your investment portfolio. The drugmaker is set to lose U.S. patent protection for its biggest cash cow -- autoimmune-disease medicine Humira -- next year.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AbbVie (NYSE: ABBV), today announced that RINVOQ is now listed as a special authorization medication or exception medication status on the formularies of Alberta1, New Brunswick2, Ontario3, Quebec4 and Saskatchewan5 for the treatment of adults with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). In addition, RINVOQ is now listed as a Limited Use product on the formulary of the Non-Insured Health Benefits program (NIHB)6 for the treatment of RA and PsA.